Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

Phase III

29 posts
NNovartis
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Read More

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

  • 2026-07-04
Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary…
RRoche
Roche divarasib tops KRAS G12C lung cancer drugs
Read More

Roche divarasib tops KRAS G12C lung cancer drugs

  • 2026-07-02
Roche (OTCQX:RHHBY) reported positive phase III Krascendo 1 results for divarasib in previously treated KRAS…
NNovartis
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Read More

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

  • 2026-06-13
Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary…
NNovartis
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Read More

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

  • 2026-06-11
Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary…
RRoche
FDA Grants Priority Review to Roche's Early-Stage Breast Cancer NDA
Read More

FDA Grants Priority Review to Roche’s Early-Stage Breast Cancer NDA

  • 2026-06-02
Roche RHHBY announced that the FDA has accepted its new drug application (NDA) for its investigational candidate, giredestrant, as…
RRoche
Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development
Read More

Roche’s fenebrutinib cuts relapses in MS amid safety concerns

  • 2026-04-22
Roche is hoping to bring the the first and only high-efficacy oral for both relapsing multiple sclerosis (RMS)…
RRoche
Genentech persevERA breast cancer trial misses PFS goal
Read More

Roche fenebrutinib cuts RMS relapses 51%-59%

  • 2026-04-22
Roche (OTCQX: RHHBY) reported that investigational fenebrutinib met primary endpoints in Phase III…
RRoche
Genentech persevERA breast cancer trial misses PFS goal
Read More

Roche ENSPRYNG cuts MOGAD relapse risk 68%

  • 2026-04-21
Roche (OTCQX: RHHBY) reported Phase III METEOROID results showing ENSPRYNG (satralizumab) reduced risk…
RRoche
Genentech persevERA breast cancer trial misses PFS goal
Read More

Genentech persevERA breast cancer trial misses PFS goal

  • 2026-04-07
03/09/2026 –…
RRoche
Genentech petrelintide sheds 10.7% weight in Phase II
Read More

Genentech fenebrutinib slashes MS relapses 51%

  • 2026-03-13
03/02/2026 – 01:10 AM – FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by…
RRoche
Roche’s Gazyva Meets Phase III SLE Endpoints at 52 Weeks
Read More

Roche lupus drug cuts disease activity in phase III

  • 2026-03-12
Roche (OTCQX: RHHBY) announced NEJM publication of phase III ALLEGORY data showing Gazyva/Gazyvaro (obinutuzumab) plus standard therapy significantly…
RRoche
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Read More

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer

  • 2026-03-10
F. Hoffmann-La Roche Ltd persevERA Breast Cancer study did not meet the primary objective of a statistically significant…
Switzerland
www.europesays.com